2011
Chimeric Anti-Staphylococcal Enterotoxin B Antibodies and Lovastatin Act Synergistically to Provide In Vivo Protection against Lethal Doses of SEB
Tilahun M, Kwan A, Natarajan K, Quinn M, Tilahun A, Xie C, Margulies D, Osborne B, Goldsby R, Rajagopalan G. Chimeric Anti-Staphylococcal Enterotoxin B Antibodies and Lovastatin Act Synergistically to Provide In Vivo Protection against Lethal Doses of SEB. PLOS ONE 2011, 6: e27203. PMID: 22102880, PMCID: PMC3216929, DOI: 10.1371/journal.pone.0027203.Peer-Reviewed Original ResearchConceptsToxic shock syndromeLethal toxic shock syndromeHLA-DR3 transgenic miceStaphylococcal enterotoxin BChimeric human-mouse antibodyShock syndromeT cellsVivo protectionTransgenic micePartial protectionComplete protectionLethal dosesT cell populationsClass II MHCSignificant partial protectionAnti-SEB antibodiesHuman T cellsOnly partial protectionInflammatory cytokinesClinical safetyII MHCB antibodiesVivo modelChimeric antibodyEnterotoxin B
2007
Derivation of synergistically acting, neutralizing, chimeric human-mouse anti-SEB monoclonal antibodies (47.35)
Tilahun M, Rajagopalan G, Osborne B, Goldsby R. Derivation of synergistically acting, neutralizing, chimeric human-mouse anti-SEB monoclonal antibodies (47.35). The Journal Of Immunology 2007, 178: s73-s73. DOI: 10.4049/jimmunol.178.supp.47.35.Peer-Reviewed Original ResearchStaphylococcal enterotoxin BEffects of SEBMonoclonal antibodiesChimeric human-mouse antibodyT cell proliferationSecretion of cytokinesT cell activationMouse monoclonal antibodySEB intoxicationHuman IVIgSynergistic neutralizationCell activationChimeric antibodyLower potencyAnti-SEB monoclonal antibodiesEnterotoxin BAntibodiesCell proliferationFood poisoningPotential agentSP2/0 cellsS. aureusNIH grantsCell linesHuman IgH